Acceleron Pharma Inc. / Fundamentals
Income statement
- Net revenue
€97.15M - Cost of goods sold
€0.00 - Gross profit
€97.15M - SG&A expenses
€118.77M - R&D expenses
€198.50M - EBITDA
-€215.91M - D&A
€3.64M - EBIT
-€220.12M - Interest expenses
€0.00 - EBT
-€219.55M - Tax expenses
€15.51K - Net income
-€219.57M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€153.61M - Changes in working capital
-€205.04M - Operating cash flow
-€225.17M - Capex
€4.48M - Other investing cash flow
€0.00 - Net investing cash flow
-€138.84M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€25.06M - Net financing cash flow
€25.06M - Foreign exchange effects
€0.00 - Net change in cash
-€338.96M - Cash at end of period
€291.08M - Free cash flow
-€220.69M
Balance sheet
- Cash and cash equivalents
€289.87M - Cash and short-term investments
€508.80M - Total receivables
€30.73M - Inventory
€0.00 - Other current assets
€60.63M - Total current assets
€600.16M - Property, plant & equipment
€23.90M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€53.37M - Other non-current assets
€1.33M - Total non-current assets
€78.61M - Total assets
€678.77M - Accounts payable
€4.38M - Short-term debt
€7.03M - Other current liabilities
€38.01M - Total current liabilities
€49.43M - Long-term debt
€10.30M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€321.36K - Total non-current liabilities
€10.62M - Total liabilities
€60.05M - Common stock
€52.55K - Retained earnings
-€926.07M - Other equity
-€342.90K - Total equity
€618.72M - Total liabilities and shareholders' equity
€678.77M
Company information
- Market capitalization
€0.00 - Employees
312 - Enterprise Value
-€646.88M
Company ratios
- Gross margin
-
100.0% Much better than peer group: 1.2% - EBITDA margin
-
-222.2% Much better than peer group: -513.7% - EBIT margin
-
-226.6% Much better than peer group: -540.2% - EBT margin
-
-226.0% Much better than peer group: -117,391.4% - Net margin
-
-226.0% Much better than peer group: -503.4% - ROE
-
-35.5% Much worse than peer group: -2.4% - ROA
-
-32.3% Much worse than peer group: -6.3% - Asset turnover
-
14.3% Much worse than peer group: 61.0% - FCF margin
-
-236.4% Much better than peer group: -391.5% - FCF yield
0.0% - Efficiency ratio
322.2% - Net sales per employee
-
€311.38K - Net income per employee
-
-€703.74K